Preparation and antimicrobial activity evaluation of some quinoline derivatives containing an azole nucleus

Article abstract of DOI:10.3906/kim-1109-9

Quinoline-2-carbohydrazide (2) obtained from quinaldic acid (1) was converted to the corresponding carbothioamide 3 and carboxamide 6 by treatment with benzyliso(thio)cyanate. The basic treatment of 3 and 6 yielded the corresponding 1,2,4-triazole derivatives 4 and 7. The synthesis of 5-(quinolin-2-yl)-1,3,4- oxadiazol-2-thiol (9) was performed from the reaction of 1 with CS2 in basic media. The Mannich reaction of compounds 4, 7, and 9 resulted in the formation of aminoalkylated derivatives 5a-c, 8, and 10a,b. The condensation of 1 with thiosemicarbazide, carbohydrazide, or thiocarbohydrazide gave the corresponding 1,2,4-triazole derivatives (11-13). The treatment of 4-amino-5-(quinolin-2-yl)-4H -1,2,4-triazole-3-thiol (13) with 4-chlorophenacyl bromide caused the formation of fused triazolothiadiazine 14. The condensation of 13 with 4-methoxybenzaldehyde generated the corresponding Schiff base 15. The newly synthesized compounds were characterized by elemental analyses, IR, ¹H-NMR, ¹³C-NMR, and mass spectra. The antimicrobial activity study revealed that some of the newly synthesized compounds showed good to moderate activity against a variety of microorganisms.

Full text of DOI:10.3906/kim-1109-9

Turk J Chem
36 (2012) , 233 – 246.
¨
˙
c
ꢀ TUBITAK
doi:10.3906/kim-1109-9
Preparation and antimicrobial activity evaluation of
some quinoline derivatives containing an azole nucleus
1
1
2
1,∗
¨
˙
1
˙
˙
Muhammet OZYANIK , Serpil DEMIRCI , Hakan BEKTAS¸ , Neslihan DEMIRBAS¸
3
˙
˘
Ahmet DEMIRBAS¸ , S¸engu¨l ALPAY KARAOGLU
1Department of Chemistry, Faculty of Sciences, Karadeniz Technical University,
61080 Trabzon-TURKEY
e-mail: neslihan@ktu.edu.tr
2Department of Chemistry, Giresun University, 28100, Giresun-TURKEY
3Department of Biology, Rize University, 53100, Rize-TURKEY
Received: 09.09.2011
Quinoline-2-carbohydrazide (2) obtained from quinaldic acid (1) was converted to the corresponding
carbothioamide 3 and carboxamide 6 by treatment with benzyliso(thio)cyanate. The basic treatment of 3
and 6 yielded the corresponding 1,2,4-triazole derivatives 4 and 7. The synthesis of 5-(quinolin-2-yl)-1,3,4-
oxadiazol-2-thiol (9) was performed from the reaction of 1 with CS2 in basic media. The Mannich reaction
of compounds 4, 7, and 9 resulted in the formation of aminoalkylated derivatives 5a-c, 8, and 10a,b. The
condensation of 1 with thiosemicarbazide, carbohydrazide, or thiocarbohydrazide gave the corresponding
1,2,4-triazole derivatives (11-13). The treatment of 4-amino-5-(quinolin-2-yl)-4H -1,2,4-triazole-3-thiol (13)
with 4-chlorophenacyl bromide caused the formation of fused triazolothiadiazine 14. The condensation of
13 with 4-methoxybenzaldehyde generated the corresponding Schiff base 15.
The newly synthesized compounds were characterized by elemental analyses, IR, 1 H-NMR, 13 C-NMR,
and mass spectra. The antimicrobial activity study revealed that some of the newly synthesized compounds
showed good to moderate activity against a variety of microorganisms.
Key Words: Quinoline, 1,3,4-thiadiazole, 1,2,4-triazole, Mannich base, antimicrobial activity
Introduction
The steadily increasing bacterial resistance to first-line antibiotic agents has become a serious problem in
antibacterial therapy and required continuing research into new classes of compounds possessing antimicrobial
activities.
∗Corresponding author
233

¨
Preparation and antimicrobial activity evaluation of..., M. OZYANIK, et al.
Infections caused by these resistant microorganisms fail to respond to treatment, resulting in prolonged
illness and greater risk of death. The growing number of reports of antibiotic resistance worldwide has led to
fears that some lethal human pathogens, such as Mycobacterium tuberculosis, will soon become untreatable.1−6
These trends have emphasized the urgent need for new, more effective, and safe antibacterial agents
and which in turn has opened up a new area of research for medicinal chemists. Besides the development of
completely new agents possessing chemical characteristics that clearly differ from those of existing ones, there
is another approach involving the combination of 2 or more biologically active heterocyclic systems in a single
molecular scaffold.7−12
Among the pharmacologically important heterocyclic compounds, quinoline and its derivatives have
been shown to possess antimalarial,13−15 antibiotic,16,17 anticancer,18 anti-inflammatory,19 antihypertensive,20
tyrosine kinase PDGF-RTK inhibition,21 and anti-HIV22,23 properties. Chloroquine, primaquine, mefloquine,
and quinine constitute notable examples of the drugs containing the quinoline scaffold that are used for the
treatment of malaria (Chart).24,25 Floroquinolones, which are closely related to the quinoline ring, constitute
another important class of antimicrobial agents used for the treatment of the infectious caused by especially
gram-negative bacteria.
NH2
N
HN
HN
N
O
Cl
N
Primaquine
HO
Chloroquine
CF3
N
CF3
CF3
H3C
N
F
N
O
H
H
H
N
H
N
OH
OH
N
Quinine
Mefloquine
Chart.
In addition, compounds incorporating a 1,2,4-triazole nucleus have been reported to possess a wide-range
spectrum of chemotherapeutic activities including anti-inflammatory,26 anticancer,27−29 antidepressant,30
antibacterial,31−35 antifungal,36 and anticonvulsant activities.37 In recent years, some studies have been re-
ported incorporating the synthesis and antimicrobial activities of compounds containing the quinoline and
triazole nucleus in a single structure.1,17,38−42 However, an extensive literature survey reveals that sufficient
efforts have not been made to combine these heterocycles in the same molecular scaffold and to investigate their
antimicrobial activity.
234

¨
Preparation and antimicrobial activity evaluation of..., M. OZYANIK, et al.
Multicomponent reactions have been considered a major part of synthetic organic chemistry with advan-
tages ranging from lower reaction times and temperatures to higher yields. The amino alkylation of aromatic
compounds by Mannich reaction has been reported to have considerable importance for designing efficient bioac-
tive molecules.43 As a part of our continuing study on the synthesis of biologically active compounds and on the
basis of the fact that more efficacious antibacterial compounds can be designed by joining 2 or more biologically
active heterocyclic systems together in a single molecular framework,44 this paper presents the synthesis of new
quinoline derivatives carrying different pharmacophores as hybrid molecules possessing antimicrobial activity.
Experimental
All the chemicals were purchased from Fluka Chemie AG Buchs (Switzerland). Melting points of the synthesized
compounds were determined in open capillaries on a Bu¨chi B-540 melting point apparatus and are uncorrected.
Reactions were monitored by thin-layer chromatography (TLC) on silica gel 60 F254 aluminum sheets. The
mobile phase was ethyl acetate and detection was conducted using UV light. IR spectra were recorded as
potassium bromide pellets using a Perkin-Elmer 1600 series FTIR spectrometer. 1 H-NMR and 13 C-NMR
spectra were recorded on a Bruker Avance II 400 MHz NMR Spectrometer (chemical shift in ppm downfield
from TMS as an internal reference). The elemental analysis was performed on a Costech Elemental Combustion
System CHNS-O elemental analyzer. The mass spectra were obtained on a Quattro LC-MS (70 eV) Instrument.
Quinoline-2-carbohydrazide (2). A solution of quinaldic acid (0.035 mol) in absolute ethanol was
stirred under reflux in the presence of 2-3 drops of sulfuric acid for 10 h. After the solvent was evaporated under
reduced pressure, a solid was obtained. This crude product was solved in 1-butanol, hydrazine hydrate (0.0875
mol) was added into it, and the mixture was refluxed for 6 h (the progress of the reaction was monitored by
TLC). On cooling the reaction content, a solid appeared. This was recrystallized from ethanol to give pure
compound. (Yield: 6.33 g, 97%); mp 136 ˚C; IR (KBr, ν , cm−1): 3294 and 3201 (NH2 +NH), 1663 (C=O),
1620 (C=N), 1498 (aromatic C=C); 1 H-NMR (DMSO-d6) δ (ppm): 4.69 (brs, 2H, NH2), 7.58-7.81 (m, 2H,
ar-H), 7.96-8.05 (m, 3H, ar-H), 8.44-8.48 (d, 1H, ar-H, J = 8.2 Hz), 10.01 (brs, 1H, NH); 13 C-NMR (DMSO-
d6) δ (ppm): ar-C:[124.05 (C), 133.32 (C), 133.45 (C), 134.04 (C), 134.61 (C), 135.82 (C), 143.11 (C), 151.45
(C), 155.43 (C)], 168.30 (C=O); MS (ESI): m/z (%) 266.03 (19), 228.99 (16), 227.99 ([M+2+K]+ , 100), 188.00
([M+1]+ , 24).
N -Benzyl-2-(quinolin-2-ylcarbonyl)hydrazincarbothioamide (3). Benzyl isothiocyanate (26
mmol) was added to a solution of compound 2 (26 mmol) in absolute ethanol and the reaction mixture was
allowed to reflux for 1 h protecting from moisture. On cooling it to room temperature, a solid was obtained.
This was recrystallized from ethanol to afford the desired compound. (Yield: 8.14 g, 93%); mp 202-203 ˚C (lit.
42, 180-182); IR (KBr, ν , cm−1): 3286 and 3152 (NH), 2978 (CH2), 1692 (C=O), 1555 (C=N), 1476 (aro-
matic C=C), 1228 (C=S); 1 H-NMR (DMSO-d6) δ (ppm): 4.69-4.72 (d, 2H, CH2 , J = 5.6 Hz), 7.20-7.29 (m,
5H, ar-H, phenyl), 7.66-7.89 (m, 3H, quinoline-C5-H, C6-H and C7-H), 8.04-8.15 (m, 2H, quinoline-C3-H and
C8-H), 8.53-8.57 (d, 1H, quinoline C4-H, J = 8.2 Hz), 8.67 (brs, 1H, NH), 9.58 (s, 1H, NH), 10.83 (s,1H, NH);
13 C-NMR (DMSO-d6) δ (ppm): 47.26 (CH2), ar-C:[119.74, 127.27, 127,73, 128.71, 128.78, 129.06, 129.54,
129.97, 131.31, 138.36, 139.95, 146.59, 150.06], 167 (C=O), 182 (C=S); MS (ESI): m/z (%) 383.12 (100), 374.86
([M+K]+ , 80), 358.91 ([M+Na]+ , 67), 338.02 ([M+2]+ , 16), 336.90 ([M+1]+ , 76), 251.71 (62), 249.77 (57),
235

¨
Preparation and antimicrobial activity evaluation of..., M. OZYANIK, et al.
229.75 (21), 209.67 (14), 187.72 (93), 162.82 (12), 134.68 (42), 127.67 (37).
4-Benzyl-5-(quinolin-2-yl)-4H-1,2,4-triazol-3-thiol (4). A solution of carbothioamide 3 (10 mmol)
in ethanol-water (1:1) was refluxed in the presence of 2 N NaOH for 3 h; then the resulting solution was cooled
to room temperature and neutralized with 37% HCl. The precipitate formed was filtered off, washed with water,
and recrystallized from dimethyl sulfoxide/water (1:1) to afford the desired compound. (Yield: 3.10 g, 96%);
mp 256-257 ˚C (lit. 42, 284-286); IR (KBr, ν , cm−1): 3061 (NH), 2911 (CH2), 2762 (SH), 1541 (C=N),
1508 (aromatic C=C); 1 H-NMR (DMSO-d6) δ (ppm): 5.99 (s, 2H, CH2), 7.13-7.25 (m, 5H, ar-H, phenyl),
7.60-8.05 (m, 5H, quinoline-C3-H, C5-H, C6-H, C7-H and C8-H), 8.37-8.41 (d, 1H, quinoline C4-H, J = 8.6 Hz),
14.44 (s, 1H, SH); 13 C-NMR (DMSO-d6) δ (ppm): 48.61 (CH2), ar-C:[120.02, 127.60, 127.76, 128.22, 128.68,
128.90, 129.57, 131.29, 137.65, 138.29, 146.06, 146.86], 148.96 (triazole C-5), 170.13 (triazole C-3); MS (ESI):
m/z (%) 357.04 ([M+K]+ , 100), 341.09 ([M+Na]+ , 16), 320.07 ([M+2]+ , 11), 319.01 ([M+1]+ , 44), 154.94
(19), 129.86 (22), 120.79 (17).
General method for the synthesis of compounds 5a-c, 8, and 10a,b. Morpholine (for 5a and
8), methylpiperazine (for 5b), 2-(morpholin-4-yl)ethanamin (for 5c), phenyl piperazine (for 10a), or methyl
piperidine-4-carboxylate (for 10b) (10 mmol) was added to a solution of compound 4 (for 5a-c), compound
7 (for 8), or compound 9 (for 10a,b) (10 mmol) in dry tetrahydrofuran and the mixture was stirred at room
temperature in the presence of formaldehyde (40%, 1.5 mL) for 3 h. Then the resulting solution was kept
overnight in cold conditions. The separated solid was collected by filtration and recrystallized from dimethyl
sulfoxide-water (1:1) (for 5a and 5b) or ethanol (for 5c, 8, and 10a,b) to yield the target compounds.
4-Benzyl-2-(morpholin-4-ylmethyl)-5-(quinolin-2-yl)-2,4-dihydro-3H-1,2,4-triazol-3-thione
(5a). (Yield: 0.76 g, 89%); mp 204-205 ˚C; IR (KBr, ν , cm−1): 2855 (CH2), 1602 (C=N), 1411 (aromatic
C=C), 1115 (C=S); Anal. Calcd. (%) for C23 H23 N5 OS: C, 66.16; N, 16.77; H, 5.55; S, 7.68. Found C, 66.29;
N, 16.43; H, 5.22; S, 7.78. 1 H-NMR (DMSO-d6) δ (ppm): 2.78 (brs, 4H, 2CH2), 3.58 (brs, 4H, 2CH2),
5.24 (brs, 2H, CH2), 6.05 (brs, 2H, CH2), 7.16-7.26 (m, 5H, ar-H, phenyl), 7.63-7.66 (m, 1H, quinoline-C6-H),
7.79-7.83 (m, 2H, quinoline-C5-H and C7-H), 7.96-8.04 (m, 2H, quinoline-C3-H and C8-H), 8.40-8.44 (m, 1H,
quinoline-C4-H); MS (ESI): m/z (%) 419.16 ([M+1]+ , 12), 340.91 (12), 418.09 ([M]+ , 40), 384.17 (20), 383.17
(100), 356.90 (18), 326.99 (14), 318.97 (16).
4-Benzyl-2-[(4-methylpiperazin-1-yl)methyl]-5-(quinolin-2-yl)-2,4-dihydro-3H-1,2,4-triazol-
3-thione (5b). Yield: 0.71 g, 81%. mp 201-203 ˚C; IR (KBr, ν , cm−1): 2929 and 2793 (aliphatic CH), 1599
(C=N), 1413 (aromatic C=C), 1169 (C=S); Anal. Calcd. (%) for C24 H26 N6 S: C, 66.95; N, 19.52; H, 6.09;
S, 7.45. Found C, 67.22; N, 19.43; H, 5.87; S, 7.21. 1 H-NMR (DMSO-d6) δ (ppm): 2.11 (s, 3H, CH3), 2.32
(s, 4H, 2CH2), 2.79 (s, 4H, 2CH2), 5.25 (s, 2H, CH2), 6.04 (s, 2H, CH2), 7.10-7.29 (m, 5H, ar-H, phenyl),
7.58-7.66 (m, 1H, quinoline-C6-H), 7.75-7.82 (m, 1H, quinoline-C7-H), 7.93-8.05 (m, 3H, quinoline-C3-H, C4-H
and C8-H), 8.36-8.42 (m, 1H, ar-H); MS (ESI): m/z (%) 453.14 ([M+Na]+ , 10), 432.32 ([M+1]+ , 29), 431.26
([M]+ , 100), 383.30 (11), 319.09 (21), 262.16 (14), 229.00 (11), 212.82 (24), 196.83 (27).
4-Benzyl-2-({[2-(morpholin-4-yl)ethyl]amino}methyl)-5-(quinolin-2-yl)-2,4-dihidro-3H-1,2,
4-triazol-3-thione (5c). Yield: 0.64 g, 76%; mp 217-218 ˚C; IR (KBr, ν , cm−1): 3435 (NH), 3060
(aromatic CH), 2952, 2852 and 2807 (aliphatic CH), 1599 (C=N), 1419 (aromatic C=C); Anal. Calcd. (%)
for C25 H28 N6 OS: C, 65.19; N, 18.25; H, 6.13; S, 6.96. Found C, 65.36; N, 18.04; H, 6.11; S, 6.67. 1 H-NMR
(DMSO-d6) δ (ppm): 2.49 (brs, 4H, 2CH2), 3.37 (brs, 8H, 4CH2), 5.68 (s, 2H, CH2), 5.94 (s, 2H, CH2),
236

¨
Preparation and antimicrobial activity evaluation of..., M. OZYANIK, et al.
6.03 (brs, 1H, NH), 7.08-7.24 (m, 5H, ar-H, phenyl), 7.62-7.99 (m, 5H, quinoline-C3-H, C5-H, C6-H, C7-H and
C8-H), 8.33-8.37 (m, 1H, quinoline-C4-H); 13 C-NMR (DMSO-d6) δ (ppm): CH2 : 47.98, 48.62, 49.54, 54.14,
56.72, 57.25, 66.78, 68.19, ar-C:[120.09, 127.57, 127.84, 128.18, 128.27, 128.63, 128.75, 128.87, 129.61, 131.34,
131.49, 137.64, 138.37, 146.90, 147.74], 145.60 (triazole C-5), 169.80 (C=S); MS (ESI): m/z (%) 475.41 (94),
473.29 (100), 461.33 ([M]+ , 10), 453.39 (19).
4-Benzyl-2-(morpholin-4-ylmethyl)-5-(quinolin-2-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one (8).
Yield: 0.86 g, 84%. mp 122-125 ˚C; IR (KBr, ν , cm−1): 2928 and 2854 (aliphatic CH), 1686 (C=O), 1602
(C=N); Anal. Calcd. (%) for C23 H23 N5 O2 : C, 68.81; N, 17.44; H, 5.77. Found C, 69.03; N, 17.28; H, 5.81.
1 H-NMR (DMSO-d6) δ (ppm): 2.64 (s, 4H, 2CH2), 3.57 (s, 4H, 2CH2), 4.74 (s, 2H, CH2), 5.62 (s, 2H, CH2),
7.15-7.33 (m, 5H, ar-H, phenyl), 7.60-8.17 (m, 5H, quinoline-C3-H, C5-H, C6-H, C7-H and C8-H), 8.38-8.57 (m,
1H, quinoline-C4-H); 13 C-NMR (DMSO-d6) δ (ppm): CH2 : 48.10, 51.30, 55.39, 71,47, 71.75, ar-C:[124.04,
131.70, 132.34, 132.42, 132.47, 132.65, 132.89, 133.20, 133.52, 133.83, 134.24, 135.97, 142.77, 143.12, 147.75],
151.69 (C=O), 160.38 (CH=N); MS (ESI): m/z (%) 475.46 (100), 453.52 (13), 424.30 ([M+Na]+ , 44), 403.36
(11), 402.29 ([M+1]+ , 40), 359.16 (12), 344.17 (17), 343.17 (75), 325.17 (25), 321.16 (19).
3-[(4-Phenylpiperazin-1-yl)methyl]-5-(quinolin-2-yl)-1,3,4-oxadiazol-2(3H)-thione (10a). Yi-
eld: 1.25 g, 79%. mp 162-163 ˚C; IR (KBr, ν , cm−1): 3064 (aromatic CH), 2821 (aliphatic CH), 1599 (C=N),
1501 (aromatic C=C), 1236 (C=S); Anal. Calcd. (%) for C22 H21 N5 O2 : C, 65.49; N, 17.36; H, 5.25. Found C,
65.62; N, 17.21; H, 5.18. 1 H-NMR (DMSO-d6) δ (ppm): 2.93 (s, 4H, 2CH2), 3.10 (s, 4H, 2CH2), 5.15 (s, 2H,
CH2), 6.69-6.89 (m, 3H, phenyl-C2-H, C4-H and C6-H), 7.11-7.19 (m, 2H, phenyl-C3-H and C5-H), 7.67-7.90
(m, 2H, quinoline-C6-H and C7-H), 8.04-8.16 (m, 3H, quinoline-C3-H, C4-H and C5-H), 8.54-8.58 (d, 1H, ar-H,
quinoline-C8-H, J = 7.8 Hz); 13 C-NMR (DMSO-d6) δ (ppm): CH2 : 48.98, 50.20, 70.68, ar-C: [116.33, 116.72,
119.55, 119.70, 128.87, 129.18, 129.56, 129.80, 129.96, 131.65, 138.66, 147.74], 151.64 (oxadiazole C-5), 167.20
(oxadiazole C2); MS (ESI): m/z (%) 414.39 (28), 413.39 (100), 411.38 (20), 402.25 ([M-1]+ , 10), 393.36 (17),
392.30 (27), 346.12 (23), 339.30 (13).
Methyl 1-{[5-(quinolin-2-yl)-2-thioxo-1,3,4-oxadiazol-3(2H)-yl]methyl}piperidin -4-carbox-
ylate (10b). Yield: 1.75 g, 83%. mp 134-137 ˚C; IR (KBr, ν , cm−1): 2948 and 2829 (aliphatic CH), 1730
(C=O), 1600 (C=N), 1439 (C=C), 1317 (C=S); Anal. Calcd. (%) for C19 H20 N4 O3 S: C, 59.36; N, 14.57;
H, 5.24; S, 8.34. Found C, 59.39; N, 14.34; H, 5.18; S, 8.37. 1 H-NMR (DMSO-d6) δ (ppm): 1.49-1.84 (m,
4H, 2CH2), 2.15-2.35 (m, 1H, O=C-CH), 2.49-2.61 (m, 2H, N-CH2), 3.02-3.07 (m, 2H, N-CH2), 3.54 (s, 3H,
OCH3), 5.01 (s, 2H, CH2), 7.66-8.15 (m, 5H, quinoline-C3-H, C4-H, C5-H, C6-H and C7-H), 8.53-8.58 (d, 1H,
quinoline-C8-H, J = 8.6 Hz); 13 C-NMR (DMSO-d6) δ (ppm): CH2 : 28.60, 49.90, 71.31, CH3 : 52.11, CH:
119.55, ar-C:[128.88, 128.96, 129.16, 129.97, 131.67, 138.70, 142.47], 147.76 (oxadiazole C-5), 175.37 (C=O),
179.03 (oxadiazole C-2); MS (ESI): m/z (%) 414.39 (23), 413.39 (100), 385.29 ([M]+ , 10), 373.22 (23).
Synthesis of N -benzyl-2-(quinolin-2-yl-carbonyl)hydrazincarboxamide (6). Benzyl isocyanate
(26 mmol) was added to a solution of compound 2 in absolute ethanol and the reaction mixture was allowed to
reflux for 4 h protecting from moisture. Then the reaction content was cooled overnight and a solid obtained.
This crude product was recrystallized from ethanol to afford the desired compound. Yield: 3.14 g, 92%. mp
205-206 ˚C; IR (KBr, ν , cm−1): 3380 and 3315 (3NH), 1716 and 1643 (C=O), 1573 (C=N), 1489 (aromatic
C=C); Anal. Calcd. (%) for C18 H16 N4 O2 : C, 67.49; N, 17.49; H, 5.03. Found C, 67.68; N, 17.23; H, 5.27. 1 H-
NMR (DMSO-d6) δ (ppm): 4.24-4.27 (d, 2H, CH2 , J = 6.0 Hz), 7.11 (s, 1H, NH), 7.20-7.31 (brs, 5H, phenyl),
237

¨
Preparation and antimicrobial activity evaluation of..., M. OZYANIK, et al.
7.68-7.91 (m, 2H, quinoline-C6-H, C7-H), 8.06-8.16 (m, 4H, quinoline-C3-H, C5-H + 2NH), 8.54-8.58 (d, 2H,
quinoline-C4-H, C8-H, J = 8.2 Hz), 10.48 (s, 1H, NH); 13 C-NMR (DMSO-d6) δ (ppm): CH2 : 43.21, ar-
C:[119.57, 127.27, 127.65, 128.77, 128.83, 129.02, 129.54, 129.99, 131.31, 138.46, 141.06, 146.64, 150.11], 158.94
(C=O), 164.87 (C=O); MS (ESI): m/z (%) 359.10 ([M+K]+ , 37), 343.03 ([M+Na]+ , 12), 321.13 ([M+1]+ ,
14), 224.00 (13), 223.00 (19), 187.91 (34), 184.90 (13), 156.82 (100), 148.81 (16), 113.91 (11), 108.84 (19),
Synthesis of 4-benzyl-5-(quinolin-2-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one (7). A solution of
carboxamide 6 (10 mmol) in ethanol/water (1:1) was refluxed in the presence of 2 N NaOH for 3 h. Then
the resulting solution was cooled to room temperature and acidified to pH 5.5 with 37% HCl. The precipitate
formed was filtered off, washed with water, and recrystallized from dimethyl sulfoxide/water (1:1) to afford the
desired compound. Yield: 1.57 g, 98%. mp 245-247 ˚C; IR (KBr, ν , cm−1): 3314 (NH), 2923 (CH2), 1697
(C=O), 1642 (aromatic C=C); Anal. Calcd. (%) for C18 H14 N4 O: C, 71.51; N, 18.53; H, 4.67. Found C, 71.79;
N, 18.74; H, 5.01. 1 H-NMR (DMSO-d6) δ (ppm): 5.60 (s, 2H, CH2), 7.29-7.64 (m, 5H, phenyl), 7.81-8.02
(m, 5H, quinoline-C3-H, C4-H, C5-H, C6-H and C7-H), 8.41 (m, 1H, quinoline-C8-H), 12.47 (s, 1H, NH); 13 C-
NMR (DMSO-d6) δ (ppm): CH2 : 45.10, ar-C:[118.40, 126.35, 126.89, 127.29, 127.53, 127.95, 128.21, 128.68,
129.14, 130.36, 137.14, 137.56, 137.90, 143.57, 146.70], 146.10 (triazole C-5), 155.56 (C=O); MS (ESI): m/z (%)
359.02 (46), 343.00 ([M+2+K]+ , 57), 325.98 ([M+1+Na]+ , 11), 325.04 ([M+Na]+ , 32), 321.04 (26), 304.08
(12), 302.95 ([M+1]+ , 40), 235.81 (23), 187.75 (21), 148.70 (21), 135.75 (12), 134.75 (100), 115.97 (14), 108.46
(28), 107.96 (39).
Synthesis of 5-(quinolin-2-yl)-1,3,4-oxadiazol-2-thiol (9). Compound 2 (10 mmol) and CS2 (10
mmol) were added to the solution of KOH (10 mmol) in 50 mL of H2 O and 50 mL of ethanol and the reaction
content was allowed to reflux for 6 h (the progress of the reaction was monitored by TLC). Then the ethanol was
removed under reduced pressure and the resulting solution was acidified with concentrated HCl. The formed
precipitate was filtered off, washed with water, and recrystallized from dimethyl sulfoxide-water (1:1) to give
the target compound. Yield: 3.14 g, 87%. mp 234-238 ˚C. IR (KBr, ν , cm−1): 3054 (aromatic CH), 2917
(aliphatic CH), 2596 (SH), 1587 and 1529 (2C=N), 1459 and 1375 (aromatic C=C); 1 H-NMR (DMSO-d6)
δ
(ppm): 7.33-8.14 (m, 5H, quinoline-C3-H, C4-H, C5-H, C6-H and C7-H), 8.53-8.58 (m, 1H, quinoline-C8-H),
14.95 (brs, 1H, SH); 13 C-NMR (DMSO-d6) δ (ppm): ar-C: [119.47, 128.88, 129.01, 129.83, 129.99, 131.69,
138.73, 142.45, 147.68], 147.79 (oxadiazole C-5), 182.12 (oxadiazole C-2); MS (ESI): m/z (%) 267.79 ([M+K]+
10), 230.80 ([M+1]+ , 14), 229.80 ([M]+ , 100), 175.67 (13), 154.77 (16), 128.74 (81), 127.74 (77), 101.77 (17).
,
Synthesis of compounds 11-13. In a round bottom flask attached to an air condenser, the mixture
of compound 1 (10 mmol) and thiocarbohydrazide (for 11), carbohydrazide (for 12), or thiocarbonohydrazide
(for 13) (10 mmol) was heated at melting temperature (about 156-160 ˚C) for 2 h. On cooling the reaction
content to room temperature, a solid was obtained. This product was washed with hot NaHCO3 solution and
recrystallized from ethanol (for 11 and 12) or dimethyl sulfoxide (for 13) to give the desired product.
5-(Quinolin-2-yl)-1,3,4-thiadiazol-2(H)-imine (11). Yield: 0.69 g, 30%. mp > 300 ˚C. Anal.
Calcd. (%) for C11 H8 N4 S: C, 57.88; N, 24.54; H, 3.53; S, 14.05. Found C, 57.82; N, 24.43; H, 3.62; S, 14.11.
IR (KBr, ν , cm−1): 3106 (2NH), 1577 and 1560 (2C=N), 1495 (aromatic C=C); 1 H-NMR (DMSO-d6)
(ppm): 7.52-7.78 (m, 2H, quinoline-C6-H and C7-H), 7.90-8.03 (m, 3H, quinoline-C3-H, C5-H, C8-H), 8.38-
8.42 (d, 1H, quinoline-C4-H, J = 8.6 Hz), 13.89 (s, 1H, NH), 14.08 (s, 1H, NH); 13 C-NMR (DMSO-d6)
δ
δ
(ppm): 118.66, 128.34, 128.58, 128.74, 129.56, 131.19, 138.30, 145.14, 147.48, 151.15 (thiadiazole C-5), 168.53
238

¨
Preparation and antimicrobial activity evaluation of..., M. OZYANIK, et al.
(thiadiazole C-2); MS (ESI): m/z (%) 267.02 ([M+K]+ , 10), 250.98 ([M+1+Na]+ , 11), 229.03 ([M+1]+ , 100),
196.89 (15), 180.79 (15), 154.94 (24), 148.90 (31), 127.89 (25), 118.84 (71).
4-Amino-5-(quinolin-2-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one (12). Yield: 1.24 g, 55%. mp >
300 ˚C. Anal. Calcd. (%) for C11 H9 N5 O: C, 58.14; N, 30.82; H, 3.99. Found C, 58.35; N, 30.56; H, 4.13.
IR (KBr, ν , cm−1): 3266 and 3145 (NH+ NH2), 1654 (C=O); 1 H-NMR (DMSO-d6) δ (ppm): 2.06 (s, 2H,
NH2), 7.71-7.77 (m, 1H, quinoline-C6-H), 7.87-7.94 (m, 1H, quinoline-C7-H), 8.08-8.22 (m, 4H, quinoline-C3-H
+ C5-H + C8-H + NH), 8.54-8.62 (m, 1H, quinoline-C4-H); 13 C-NMR (DMSO-d6) δ (ppm): 122.88, 126.42,
126.92, 129.47, 131.14, 133.69, 134.75, 137.13, 143.11, 145.56 (triazole C3), 155.12 (triazole C5); MS (ESI): m/z
(%) 279.15 (18), 278.15 (10), 234.00 (16), 232.99 (91), 164.00 (43), 151.98 (25), 106.89 (82).
4-Amino-5-(quinolin-2-yl)-4H-1,2,4-triazole-3-thiol (13). Yield: 1.36 g, 56%. mp 213 ˚C. IR
(KBr, ν , cm−1): 3258 and 3077 (NH2 + aromatic CH), 2918 (aliphatic CH), 2763 (SH), 1595 and 1545
(2C=N), 1493 (aromatic C=C), 1212 (C=S); Anal. Calcd. (%) for C12 H10 N4 S: C, 59.48; N, 23.12; H, 4.16.
Found C, 59.65; N, 23.16; H, 4.12. 1 H-NMR (DMSO-d6) δ (ppm): 6.69 (s, 2H, NH2), 7.69-7.85 (m, 2H,
quinoline-C6-H, C7-H), 8.03-8.17 (m, 3H, quinoline-C3-H, C5-H, C8-H), 8.53-8.57 (d, 1H, quinoline-C4-H, J =
8.6 Hz), 14.20 (brs, 1H, SH); due to the slight solubility in any NMR solvent, a satisfactory 13 C-NMR spectrum
could not be obtained; MS (ESI): m/z (%) 284.20 (19), 282.06 ([M+K] + , 81), 265.96 ([M+Na]+ , 44), 262.00
(11), 248.04 (20), 244.02 ([M+1]+ , 60), 228.92 (16), 225.90 (34), 224.90 (22), 203.70 (11), 193.89 (11), 168.80
(18), 156.91 (37), 152.89 (57), 148.93 (11), 134.84 (39), 105.85 (26), 100.88 (100).
2-[6-(4-Chlorophenyl)-8H-[1,2,4]triazolo[4,3-d][1,3,4]thiadiazin-3-yl]quinoline (14). The mix-
ture of compound 13 (10 mmol) and 4-chlorophenacylbromide (10 mmol) in absolute ethanol was allowed to
reflux in the presence of dried sodium acetate (20 mmol) for 12 h. Then the mixture was allowed to reach to
room temperature and the solid formed was filtered off, washed with water several times, and recrystallized
from ethyl acetate to afford the desired compound. Yield, 2.43 g, 68%. mp 204-206 ˚C. Anal. Calcd. (%)
for C19 H12 ClN5 S: C, 60.40; N, 18.53; H, 3.20; S, 8.49. Found C, 60.57; N, 18.45; H, 3.22; S, 8.56. IR (KBr,
ν , cm−1): 3087 (ar-CH), 1693, 1645 and 1587 (HC=N); 1 H-NMR (DMSO-d6) δ (ppm): 4.49 (s, 2H, CH2),
7.63-7.74 (m, 4H, ar-H), 7.74-7.86 (m, 1H, ar-H), 8.04-8.10 (m, 4H, ar-H), 8.56-8.61 (m, 1H, ar-H), 13 C-NMR
(DMSO-d6) δ (ppm): 23.29 (CH2), ar C: [128.82 (2CH), 129.97 (2CH), 130.16 (2CH), 131.34 (2CH), 137.92
(2CH), 145.20 (C), 145.62 (C), 149.23 (C), 154.04 (C), 155.10 (ar-C + triazole C5), 145.05 (ar-C + triazole
C3)]. 108.17 (90.62), 115.80 (48.12), 132.82 (30.00), 148.84 (26.25), 180.87 (26.25), 196.83 (48.75), 199.52
(40.62), 212.03 (35.00), 214.85 (23.12), 246.14 (24.37), 271.16 (20.00), 318.22 (49.37), 334.23 (54.30), 336.30
(34.37), MS (ESI): m/z (%) 457.37 (30), 416.20 ([M-1+K], 23.12), 399.24 (32.5), 383.29 (48.12), 378.16 ([M+ ],
100).
4-{[(4-Methoxyphenyl)methylidene]amino}-5-(quinolin-2-yl)-4H-1,2,4-triazole-3-thiol (15).
In a round bottom flask attached to an air condenser, the mixture of compound 13 (10 mmol) and 4-
methoxybenzaldehyde (10 mmol) was heated at 120 ˚C for 2 h. On cooling the reaction content to room
temperature, a solid was obtained. This crude product was recrystallized from dimethyl sulfoxide to give the
desired product. Yield, 2.26 g, 62%. mp 253 ˚C. Anal. Calcd. (%) for C19 H15 N5 OS: C, 63.14; N, 19.38; H,
4.18; S, 8.87. Found C, 63.38; N, 19.21; H, 4.24; S, 8.71. IR (KBr, ν , cm−1): 2829 (SH), 3060 (ar-CH), 1607,
1567 and 1504 (C=N), 1258 (C-O); 1 H-NMR (DMSO-d6) δ (ppm): 3.86 (s, 3H, CH3), 7.06-7.09 (m, 2H,
phenyl-C3-H, C5-H), 7.68-8.09 (m, 7H, phenyl-C2-H + C6-H + quinoline), 8.50-8.51 (m, 1H, quinoline-C4-H),
239

¨
Preparation and antimicrobial activity evaluation of..., M. OZYANIK, et al.
9.30 (s, 1H, HC=N), 14.32 (s, 1H, SH); due to the slight solubility in any NMR solvent, a satisfactory 13 C-NMR
spectrum could not be obtained. MS (ESI): m/z (%) 413.39 (100), 384.24 ([M+Na]+ , 13), 363.20 (21), 362.20
([M+1]+ , 86), 301.13 (10), 230.05 (12), 228.99 (80), 154.91 (16), 148.78 (16), 118.81 (33).
Antimicrobial activity assessment
All test microorganisms were obtained from the Refik Saydam Hygiene Institute (Ankara, Turkey) and were
as follows: E. coli ATCC35218, E. aerogenes ATCC13048, Y. pseudotuberculosis ATCC911, P. aeruginosa
ATCC43288, S. aureus ATCC25923, E. faecalis ATCC29212, B. cereus 709 Roma, M. smegmatis ATCC607,
C. albicans ATCC60193, C. tropicalis ATCC 13803, A. niger RSKK 4017, and S. cerevisiae RSKK 251. All
the newly synthesized compounds were weighed and dissolved in dimethyl sulfoxide to prepare extract stock
solution of 5.000 mg/mL. Agar-well diffusion method screening test using agar-well diffusion45 as adapted
earlier46 was used for all newly synthesized compounds. Each microorganism was suspended in Mueller Hinton
(MH) (Difco Detroit, MI, USA) broth and diluted approximately to 106 colony forming units (cfu)/mL. They
were flood-inoculated onto the surface of the MH agar and Sabouraud Dextrose Agar (SDA) (Difco, Detriot,
MI, USA) and then dried. For C. albicans and C. tropicalis, SDA was used. Five millimeter diameter wells were
cut from the agar using a sterile cork-borer, and 50 mL of the extract substances was delivered into the wells.
The plates were incubated for 18 h at 35 ˚C. Antimicrobial activity was evaluated by measuring the zone of
inhibition against the test organism. Ampicillin (10 mg), Streptomycin (10 mg), and Fluconazole (5 mg) were
the standard drugs. Dimethyl sulfoxide and ethanol were used as solvent controls.
Results and discussion
The synthesis of the target compounds was carried out as outlined in Schemes 1 and 2.
Compounds 1-4 and 9 are commercially available. The synthesis of compounds 3 and 6 was performed
by the reaction of 2 with benzylisothiocyanate (for 3) or benzylisocyanate (for 6). The products 3 and 6
were characterized by their physical, analytical, and spectral data. IR spectra of these compounds showed
NH stretching bands between 3380 and 3152 cm−1 . The absorption bands associated with other functional
groups appeared in the expected regions. In the 1 H-NMR spectra of the target carbo(thio)amides, the NH
protons appeared between 8.67 and 10.48 ppm as D2 O exchangeable singlets. The intramolecular cyclization
of 3 and 6 was performed by basic treatment of these intermediates under reflux conditions. It is well known
that 4 type of compounds exist as their thion-mercapto tautomeric forms, and the SH signal due to thiol form
is a more downfield singlet than the NH signal derived from thione form.7,30−33 In the 1 H-NMR spectrum
of 4, the appearance of one signal observed at 14.44 ppm integrating one proton indicated that the dominant
form for compound 4 is the mercapto form. The other protons appeared at the expected chemical shifts and
integral values as D2 O nonexchangeable signals. In the IR spectrum of 7, the presence of a stretching band
representing NH and C=O functionalities at 3314 and 1692 cm−1 and the absence of any signals due to a
OH group demonstrated that the dominant tautomeric form of compound 7 is keto form. Moreover, no signal
originating from a OH group was recorded in the 1 H-NMR spectrum of 7, while the NH group of compound
7 resonated at 12.47 ppm integrating one proton. The endocyclic C=O (triazole C-3) was observed at 155.56
ppm in the 13 C-NMR spectrum of 7. These observations are consistent with the literature.7,29,32−36
240

¨
Preparation and antimicrobial activity evaluation of..., M. OZYANIK, et al.
S
O
N
CONHNH
NH
N
CONHNH
NH
3
6
v
vi
iii
ii
N
CONHNH2
N
N
N
NH
2
N
N
N
N
SH
O
4
i
7
vii
iv
N
COOH
1
R
N
viii
N
O
N
N
N
N
N
N
N
S
O
N
NH
N
S
O
5a-c
9
8
5a: R=
N
N
O
ix
N
CH3
5b: R=
5c: R=
R
N
N
(CH2)2
N
O
N
S
O
10a,b
10a: R=
N
N
O
OCH3
10b: R=
N
Scheme 1. Reaction and conditions: i) H2 NNH2 , ii) benzylisothiocyanate, iii) NaOH, iv) CH2 O and morpholine
(for 5a), methyl piperazine (for 5b) or 2-(morpholin-4-yl)ethylamine (for 5c), v) benzylisothiocyanate, vi) NaOH, vii)
CH2 O and morpholine, viii) CS2 , ix) CH2 O and phenyl piperazine (for 10a) or methyl piperidine-4-carboxylate (for
10b).
The base catalyzed cyclocondensation of hydrazide (2) with carbondisulfide generated 1,3,4-oxadiazole
derivative (9) in good yield under reflux conditions. This compound (9) exhibited spectral data consistent with
its structure.
The attempts for aminoalkylations of triazole and oxadiazole derivatives (4, 7, and 9) by Mannich
reaction allowed the isolation of the corresponding products (5a-c, 8, and 10a,b) in good yields, after 3 h
241

¨
Preparation and antimicrobial activity evaluation of..., M. OZYANIK, et al.
at room temperature. Different from 4, 7, and 9, the NMR spectra of the obtained Mannich bases (5a-c,
8, and 10a,b) displayed additional signals derived from the amine moiety and -CH2 - linkage at the related
shift and integral values as D2 O nonexchangable signals, while the SH(NH) signals disappeared. Due to the
lower solubility in any NMR solvent, no satisfactory 13 C-NMR spectrum could be obtained for 5a,b. These
compounds displayed elemental analysis data consistent with their structures.
N
N
N
S
N
N
iv
N
N
i
N
1
COOH
N
N
SH
NH2
Cl
v
13
14
ii
iii
N
N
N NH
N
N
SH
N
NH
N
N
N
O
N
S
NH
NH2
CH
11
12
OCH3
15
Scheme 2. Synthesis of compounds 11-15. i) thiocarbohydrazide, ii) thiosemicarbazide, iii) carbohydrazide, iv)
4-chlorophenacylbromide, v) 4-methoxybenzaldehyde.
The heating in the solvent free media of quinaldic acid (1) with thiocarbohydrazide to melting temperature
led to the formation of 4-amino-5-(quinolin-2-yl)-4H-1,2,4-triazole-3-thiol (13); while the treatment of the same
precursor with carbohydrazide yielded 4-amino-5-(quinolin-2-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one (12) in the
same reaction conditions. On the other hand, the cyclocondensation of 1 with thiosemicarbazide afforded
5-(qinolin-2-yl)-1,3,4-thiadiazol-2(H)-imine (11). The IR and NMR spectra of compounds 11-13 displayed
additional signals derived from NH2 , NH, and/or SH functionalities as D2 O exchangeable signals. The reaction
of 13 with 4-chlorophenacyl bromide caused fusion between the NH2 and SH groups and acyl nucleus; thus,
2-[6-(4-chlorophenyl)-8H-[1,2,4]triazolo[4,3-d][1,3,4]thiadiazin-3-yl]quinoline (14) formed. In the IR spectra of
compound 14, the absence of any absorption bands originating from –SH and –NH2 stretching frequencies
clearly indicated fusion between compound 13 and 4-chlorophenacyl bromide. Furthermore, additional signals
in the aromatic region were observed due to the 4-chlorophenyl nucleus.
242

¨
Preparation and antimicrobial activity evaluation of..., M. OZYANIK, et al.
The condensation of 13 with 4-methoxybenzaldehyde at melting temperature in the solvent-free media
afforded the corresponding Schiff base, 4-{[(4-methoxyphenyl)methylidene]amino}-5-(quinolin-2-yl)-4H-1,2,4-
triazole-3-thiol (15). The IR and 1 H-NMR spectra of compound 15 exhibited no signal belonging to a NH2
group, while additional signals originating from the 4-methoxyphenyl nucleus were recorded in the related
chemical shift values.
Additional support for the formation of the targeted compounds was obtained by the appearance of
[M]+ , [M+1]+ , [M+Na]+ , and/ or [M+K]+ ion peaks at corresponding m/z values confirming their molecular
masses.
Antimicrobial activity
All the newly synthesized compounds were tested for their antimicrobial activities and the results obtained are
presented in the Table. Among the synthesized compounds, compounds 5a-c displayed no activity against the
test microorganisms. The highest activity was observed for compound 11, which contains a 1,3,4-thiadiazole
Table. Screening for antimicrobial activity of the new compounds (mm).
Microorganisms and inhibition zone (mm)
Comp. no
Ec Ea Yp Pa Sa Ef Bc Ms Ca
Sc
-
5a
5b
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5c
-
-
-
-
-
6
8
6
6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
7
10 10 10
10 10 10
8
-
10
10
8
10a
10b
11
8
8
6
6
8
-
8
-
10 10 10 10
-
-
-
10
8
6
-
10 10 16 16
8
6
8
12
10
6
8
6
6
8
8
6
8
8
8
8
8
10 10 10
13
-
-
-
-
-
-
-
14
8
-
15
10 10
6
6
-
Amp.
Strep.
Flu
10 10 18 18 35 10 15
35
25 > 25
Ec: Escherichia coli ATCC 25922, Ea: Enterobacter aerogenes ATCC 13048 Yp: Yersinia pseudotuberculosis ATCC
911, Pa: Pseudomonas aeruginosa ATCC 43288, Sa: Staphylococcus aureus ATCC 25923, Ef: Enterococcus faecalis
ATCC 29212, Bc: Bacillus cereus 702 Roma, Ms: Mycobacterium smegmatis ATCC607, Ca: Candida albicans ATCC
60193, Sc: Saccharomyces cerevisiae RSKK 251, Amp.: Ampicillin, Strep.: Streptomycin, Flu.: Fluconazole.
243

¨
Preparation and antimicrobial activity evaluation of..., M. OZYANIK, et al.
skeleton and an imine functionality in its structure. When compared to the standard drug ampicillin, com-
pounds 7, 8, and 11 were found to have equal activity against enteric bacteria, Escherichia coli (Ec) and
Enterobacter aerogenes (Ea). Very good activity was observed for compound 11 on Yersinia pseudotuberculosis
(Yp) and Pseudomonas aeruginosa (Pa), while promising activities were observed for 7 and 8 towards Yp. In
fact, compound 7, a 1,2,4-triazol-3-one derivative, and its Mannich base (8) incorporating morpholine moiety
exhibited similar activities against Escherichia coli (Ec), Enterobacter aerogenes (Ea), Yersinia pseudotuber-
culosis (Yp), and a nonpigmented rapidly growing mycobacterium, Mycobacterium smegmatis (Ms), activity.
This result showed that the introduction of morpholine moiety into the structure did not contribute to the
activity of compound 7. In fact, for compound 8, this structural modification caused loss of activity towards
Staphylococcus aureus (Sa), which is a gram-positive coccus.
Among the Mannich base derivatives (10a,b) of compound 9, 10a displayed good-moderate activity
towards the test microorganisms except Ca and Sc, which are yeast-like fungi, while compound 10b showed
activity against only Ec, Ea, and Ms. The activity of 10a on Enterococcus faecalis (Ef ) was equal to the
activity of ampicillin. When compared to ampicillin, the 4-amino-1,2,4-triazol-3-one compound (12) exhibited
equal activity on Ec and Ef, which are gram-positive cocci, and promising activity on Bacillus cereus (Bc),
which is a gram-positive spore bacillus, while moderate-slight activities were observed against the other test
microorganisms except Ca and Sc.
Compounds 13-15 were found to be active against some of the test microorganisms. The activity of 15
towards Ec and Ea was equal to that of ampicillin. None of the newly synthesized compounds demonstrated
activity on yeast-like fungi, Ca and Sc.
Acknowledgement
Support was provided by Karadeniz Technical University, BAP, Turkey (Ref. No. 2007.111.002.5).
References
1. Thomas, K. D.; Adhikari, A. V.; Shetty, N. S. Eur. J. Med. Chem. 2010, 45, 3803-3810.
2. Narender, P.; Srinivas, U.; Ravinder, M.; Rao, B. A.; Ramesh, C.; Harakishore, K.; Gangadasu, B.; Murthy, U. S.
N.; Rao, V. J. Bioorg. Med. Chem. 2006, 14, 4600-4609.
3. Dye, C.; Williams, H, B. G. Sci. Trans. Med. 2009, 1, Artic. Num. 3ra8 DOI: 10.1126/scitranslmed.3000346.
4. Dye, C. Lancet 2006, 367, 938-940.
¨
5. Koca, M.; Servi, S.; Kirilmis, C.; Ahmedzade, M.; Kazaz, C.; Ozbek, B.; Otu¨k, G. Eur. J. Med. Chem. 2005, 40,
¨
1351-1358.
6. Zalavadiya, P.; Tala, S; Akbari, J.; Joshi, H. Arch. Pharm. Chem. Life Sci. 2009, 342, 469-475.
7. Bayrak, H.; Demirbas, A.; Demirbas, N.; Alpay-Karaoglu, S. Eur. J. Med. Chem. 2010, 45, 4726-4732.
8. Solomon, V. R.; Hu, C.; Lee, H. Bioorg. Med. Chem. 2010, 18, 1563-1572.
9. Hu, C.; Solomon, V. R.; Ulibarri, G.; Lee, H. Bioorg. Med. Chem. 2008, 16, 7888-7893.
244

¨
Preparation and antimicrobial activity evaluation of..., M. OZYANIK, et al.
10. Hu, C.; Solomon, V. R.; Cano, P.; Lee, H. Eur. J. Med. Chem. 2010, 45, 705-709.
11. Kouznetsov, V. V.; Gomez-Barrio, A. Eur. J. Med. Chem. 2009, 44, 3091-3113.
12. Adamec, J.; Beckert, R.; Weiss, D.; Klimesova, V.; Waisser, K.; M¨ollmann, U.; Kaustova, J.; Buchta, V. Bioorg.
Med. Chem. 2007, 15, 2898-2906.
13. Lamontagne, M. P.; Markovac, A.; Khan, M. S. J. Med. Chem. 1982, 25, 964-968.
14. Lamontagne, M. P.; Blumbergs, P.; Strube, R. E. J. Med. Chem. 1982, 25, 1094-1097.
15. Nasveld, P.; Kitchener, S. Trans. R. Soc. Trop. Med. Hyg. 2005, 99, 2-5.
16. Mahamoud, A.; Chevalier, J.; Davin-Regli, A.; Barbe, J.; Pages, J. M. Curr. Drug Targets 2006, 7, 843-847.
17. Eswaran, S.; Adhikari, A. V.; Shetty, N. S. Eur. J. Med. Chem. 2009, 44, 4637-4647.
18. Chen, Y. L.; Chen, I. L; Wang, T. C.; Han, C. H.; Tzeng, C. C. Eur. J. Med. Chem. 2005, 40, 928-934.
19. Leatham, P. A.; Bird, H. A.; Wright, V.; Seymour, D.; Gordon, A. Eur. J. Rheumatol. Inflamm. 1983, 6, 209-211.
20. Muruganantham, N.; Sivakumar, R.; Anbalagan, N.; Gunasekaran, V.; Leonard, J. T. Biol. Pharm. Bull. 2004,
27, 1683-1687.
21. Maguire, M. P.; Sheets, K. R.; McVety, K.; Spada, A. P.; Zilberstein, A. J. Med. Chem. 1994, 37, 2129-2137.
22. Strekowski, L.; Mokrosz, J. L.; Honkan, V. A.; Czarny, A.; Cegla, M. T.; Patterson, S. E.; Wydra, R. L.; Schinazi,
R. F. J. Med. Chem. 1991, 34, 1739-1746.
23. Kacprzak, K. Synlett 2005, 6, 943-946.
24. Graves, P. R.; Kwiek, J. J.; Fadden, P.; Ray, R.; Hardeman, K.; Coley, M. A.; Foley, M.; Haystead T. A. J. Mol.
Pharmacol. 2002, 62, 1364-1372.
25. Amit, N.; Vikramdeep, M.; Alpeshkumar, M.; Evans, C.; Rahul, J. Bioorg. Med. Chem. 2007, 15, 626-640.
26. Mathew, V.; Keshavayya, J.; Vaidya, V. P.; Giles, D. Eur. J. Med. Chem. 2007, 42, 823-840.
27. Howell, A.; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M.; Forbes, J. F.; Hoctin-Boes, G.; Houghton, I.; Locker,
G.Y. Tobias, J. S. Lancet 2005, 365, 60-62.
28. Demirbas, N.; Ugurluoglu, R.; Demirbas, A. Bioorg. Med. Chem. 2002, 10, 3717-3723.
29. Demirbas, N.; Demirbas, A.; Alpay-Karao˘glu, S. Russian J. Bioorg. Chem. 2005, 31, 387-397.
30. Przegalinski, E.; Lewandowska, A. J. Neural Transm. 1979, 46, 303-312.
31. Bayrak, H.; Demirbas, A.; Alpay Karaoglu, S.; Demirbas, N. Eur. J. Med. Chem. 2009, 44, 1057-1066.
32. Bayrak, H.; Demirbas, A.; Demirbas, N.; Alpay Karaoglu, S. Eur. J. Med. Chem. 2009, 44, 4362-4366.
33. Bayrak, H.; Demirba¸s, A.; Bekta¸s, H.; Alpay-Karao˘glu, S.; Demirba¸s, N. Turk. J. Chem. 2010, 34, 835-846.
34. Demirbas, A.; Sahin, D.; Demirbas, N.; Alpay Karaoglu, S. Eur. J. Med. Chem. 2009, 44, 2896-2903.
35. Bektas, H.; Karaali, N.; Sahin, D.; Demirbas, A.; Alpay-Karaoglu, S.; Demirbas, N. Molecules, 2010, 15, 2427-2438.
36. Ikizler, A.; Demirbas, N.; Ikizler, A. A. J. Heterocyclic Chem. 1996, 33, 1765-1769.
37. Almasirad, A.; Tabatabai, S. A.; Faizi, M.; Kebriaeezadeh, A.; Mehrabi, N.; Dalvandi, A.; Shafiee, A. Bioorg. Med.
Chem. Lett. 2004, 14, 6057-6059.
38. Holla, B. S.; Mahalinga, M.; Karthikeyan, M. S.; Poojary, B.; Akberali, P. M.; Kumari, N. S. Eur. J. Med. Chem.
2005, 40, 1173-1178.
39. Thomas, K. D.; Adhikari, A. V.; Chowdhury, I. H.; Sumesh, E.; Pal, N. K. Eur. J. Med. Chem. 2011, 46, 2503-2512.
245

¨
Preparation and antimicrobial activity evaluation of..., M. OZYANIK, et al.
40. Kategaonkar, A. H.; Shinde, P. V.; Kategaonkar, A. H.; Pasale, S. K.; Shingate, B. B.; Shingare, M. S. Eur. J.
Med. Chem. 2010, 45, 3142-3146.
41. Gupta, M. Bioorg. Med. Chem. Lett. 2011, 21, 4919-4923.
42. Keshk, E. M.; El-Desoky, S. I.; Hammouda, M. A. A.; Abdel-Rahman, A. H.; Hegazi, A. G. Phosphorus, Sulfur,
and Silicon, 2008, 183, 1323-1343.
43. Ashok, M.; Holla, B. S.; Poojary, B. Eur. J. Med. Chem. 2007, 42, 1095-1101.
44. Xie, J.; Seto, C. T. Bioorg. Med. Chem. 2007, 15, 458-473.
45. Perez, C.; Pauli, M.; Bazerque, P. Acta Biol. Med. Experimentalis 1990, 15, 113-115.
46. Ahmad, I.; Mehmood, Z.; Mohammed, F. J. Ethnopharmacology 1998, 62, 183-193.
246

Copyright of Turkish Journal of Chemistry is the property of Scientific and Technical Research Council of
Turkey and its content may not be copied or emailed to multiple sites or posted to a listserv without the
copyright holder's express written permission. However, users may print, download, or email articles for
individual use.